International audience
-
February 2019 (v1)Journal articleUploaded on: December 4, 2022
-
December 15, 2019 (v1)Journal article
Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real-life cohort of 16,703 consecutive MBC patients initiating their first...
Uploaded on: December 4, 2022 -
April 2021 (v1)Journal article
International audience
Uploaded on: December 4, 2022 -
2020 (v1)Journal article
Background: Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)).Methods: ESME MBC database is a national cohort, collecting retrospective...
Uploaded on: December 3, 2022 -
February 21, 2019 (v1)Journal article
Purpose The currently ongoing Epidemiological Strategy and Medical Economics (ESME) research programme aims at centralising real-life data on oncology care for epidemiological research purposes. We draw on results from the metastatic breast cancer (MBC) cohort to illustrate the methodology used for data collection in the ESME research...
Uploaded on: December 4, 2022 -
February 2021 (v1)Journal article
Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC).Methods: The National ESME-MBC observational cohort includes all consecutive patients newly...
Uploaded on: December 4, 2022 -
January 2020 (v1)Journal article
The aims of the present study were to describe treatment patterns and survival outcomes in patients with central nervous system metastases (CNSM) selected among metastatic breast cancer (MBC) patients included in a retrospective study from the Epidemiological Strategy and Medical Economics (ESME) MBC cohort.
Uploaded on: December 3, 2022 -
April 2020 (v1)Journal article
The impact of locoregional treatment (LRT) on overall survival (OS) in de novo metastatic breast cancer (dnMBC) is still under debate, with very few data available regarding exclusive radiotherapy (ERT) as a therapeutic modality.
Uploaded on: December 4, 2022 -
April 2020 (v1)Journal article
Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC).
Uploaded on: December 4, 2022